Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group (Q42550309)
Jump to navigation
Jump to search
scientific article published on February 1997
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group |
scientific article published on February 1997 |
Statements
1 reference
Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group (English)
1 reference
G Brufman
1 reference
E Colajori
1 reference
N Ghilezan
1 reference
M Lassus
1 reference
A Martoni
1 reference
N Perevodchikova
1 reference
C Tosello
1 reference
D Viaro
1 reference
C Zielinski
1 reference
1 February 1997
1 reference
1 reference
Identifiers
1 reference